Sentences with phrase «treatment slowed the development»

LPE treatment slowed the development of brown spots on the peel tissue.»

Not exact matches

During the 1970s, DuPont worked to expand Endo's line of analgesics and to develop treatments for drug addiction, but Endo proved unable to accommodate the expansion and squabbling among research groups slowed development of new drugs.

In the end, such low clinical trial enrollment — only 3 to 5 percent of all cancer patients — slows the development of new treatments, says Ellen Stovall of the National Coalition for Cancer Survivorship.

The current system discourages high - risk, high - payoff science and the publishing of crucial but less grant - worthy negative findings, slowing development of medical treatments.

Adding to these challenges: the development of new beneficial microbes and microbiome - related treatments has been slow.

One of the main challenges in finding a treatment for the disease in the future is the research and development of pharmacological therapies capable of activating the Crtc1 protein, with the aim of preventing, slowing down or reverting cognitive alterations in patients.

To the degree that poor sleep promotes the development of Alzheimer's disease, treatments for poor sleep or efforts to maintain healthy sleep patterns may help prevent or slow the progression of Alzheimer disease,» said Spira.

«This does not prove that it would be an effective treatment, but it generates a hypothesis that in the future we might be able to slow down the development of cancer or inflammation by using these medicines in combination with other treatments,» says Bratlie.

There are currently limited treatments to prevent or delay declining cognition or dementia due to vascular disease, but if risk is identified early, then development of these diseases might be slowed with lifestyle adjustments and treatments for risk factors like blood pressure.

The development of antiretroviral therapy, a combination of drugs that slows the replication of HIV in the body, has transformed the treatment of this infection.

Their compound, which is intended to repair brain damage that has already occurred, is a significant departure from current Alzheimer's treatments, which either slow the process of cell death or inhibit cholinesterase, an enzyme believed to break down a key neurotransmitter involved in learning and memory development.

Novel activators of this molecular pathway will be evaluated in a pre-clinical animal model of AMD to determine if treatment is effective in preventing or slowing the development of AMD - like pathologies.

The operationalization of mild cognitive impairment (MCI) led to targeting earlier symptomatic cases of the illness and treatment strategies based less on pathology and more on a chance to halt or slow decline than there would be earlier in the disease.1 With the development of amyloid imaging, MCI due to AD diagnosis was refined, 2 and early - stage AD was extended further to include preclinical AD, 3 wherein a positive amyloid positron emission tomography (PET) scan or diagnostic low levels of cerebrospinal fluid β - amyloid (Aβ) indicated the presence of pathology in people who were cognitively normal.

One way to provide correct treatment and slow down the development of antibiotic resistance is to assay the susceptibility profile of the infecting bacteria before treatment is initiated and let this information guide the choice of antibiotic.

Despite ongoing efforts toward finding novel entities for the treatment of the most challenging cancers, translation into patient benefit has been slow due to the fact that translational cancer research from early drug discovery to late stage drug development and assessment in clinical trials is a long process.

Treatment focuses on managing oxalate levels and hydration in order to slow the development of kidney disease.

Failure to understand the underlying cause of mitral valve degeneration has slowed the development of effective treatment and prevention plans.

This early treatment can slow the progression of some disease states and minimize the development of compensatory problems.

In the Kojima vs Konami feud I side with Kojima»cause Konami treatment toward its workers was extremely unethical plus they didn't let the game to be completed, but there might be more to the story than we know, Kojima was no saint either, he burned through a lot of money missing deadline after deadline and acting like a loose cannon, the gamble on this game was pretty high, alas a slow development was to be expected»cause the team was managing all the ports of the game while using their own engine.

This misapplication of PPC has created some blemishes that have plagued the peer group treatment modality (Quigley, 2003), causing a reversal of the once historic lightning spread of peer helping programs and slowing the development of a practice that has deep roots in child development theory.